Tenofovir alafenamide

(Vemlidy®)

Vemlidy®

Drug updated on 11/13/2023

Dosage FormTablet (oral; 25 mg)
Drug ClassNucleoside analog reverse transcriptase inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of chronic hepatitis B virus infection in adults and pediatric patients 12 years of age and older with compensated liver disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Vemlidy (tenofovir alafenamide) Prescibing Information.2022Gilead Sciences, Inc. Foster City, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines